Skip to main content
. 2020 Sep 6;12(9):2532. doi: 10.3390/cancers12092532

Table 1.

Patient characteristics at baseline.

Characteristic (n Patients) Overall (227) France (134) Italy (93) p-Value
Median Age (IQR) 59 (53, 62) 59 (53, 62) 58 (52, 62) 0.573
Random Assignment (%)
  • -

    Bortezomib Intensification

  • -

    Autograft

  • -

    Missing Data

94 (41.4)

124 (54.6)
10 (4.0)		 72 (53.7)

61 (45.5)
1 (0.8)		 22 (23.7)

63 (67.7)
8 (8.6)		 < 0.001
ISS n (%)
  • -

    Stage I

  • -

    Stage II

  • -

    Stage III

102 (45.2)
89 (39.0)
36 (15.8)		 57 (42.5)
57 (42.5)
20 (14.9)		 45 (48.9)
32 (34.0)
16 (17.0)		 0.424
R-ISS n (%)
  • -

    Stage I

  • -

    Stage II

  • -

    Stage III

  • -

    Missing Data

54 (23.7)
124 (54.7)
24 (10.6)
25 (11.0)		 27 (20.2)
74 (55.2)
14 (10.4)
19 (14.2)		 27 (29.1)
50 (53.7)
10 (10.7)
6 (6.5)		 0.135
LDH (U/L) (median (IQR)) 31.00
(166, 337)		 211.80
(159, 327)		 263.50
(179, 365)		 0.093
High Risk Cytogenetics FISH
N (%) (del(17p), t(4;14), t(14;16)) 		6 (14.0) 11 (10.7) 15 (18.1) 0.202
β2m mg/L (median (IQR)) 3.20
(2.40, 4.45)		 3.25
(2.61, 4.48)		 3.10
(2.21, 4.38)		 0.405
Albumin g/dL (median (IQR)) 3.86
(3.45, 4.26)		 3.77
(3.39, 4.23)		 3.95
(3.50, 4.40)		 0.034
Platelets (median (IQR)) 232.00
(189.5, 282.5)		 233.00
(194.0, 279.0)		 225.50
(176.3, 282.8)		 0.400

ISS: International Staging System; R-ISS: revised International Staging System, LDH: Lactate dehydrogenase; β2m: β2microglobulin.